此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome (BIC-LIDO-MPS)

2026年5月1日 更新者:Ola mohamed abdelfatah、Cairo University

Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome Using Surface Electromyography (sEMG)

This study is designed to evaluate a method to improve the treatment of myofascial pain syndrome (MPS), a common condition that causes muscle pain, tenderness, and reduced movement due to the presence of trigger points in muscles.

A commonly used treatment for this condition is the injection of a local anesthetic called lidocaine into these trigger points to relieve pain. However, the pain relief from lidocaine alone may be temporary.

In this study, we are investigating whether adding a small amount of sodium bicarbonate to lidocaine can improve its effectiveness. Sodium bicarbonate may reduce the pain during injection and help the anesthetic work faster and possibly last longer.

Participants in this study will be randomly assigned into one of two groups:

One group will receive lidocaine alone. The other group will receive lidocaine mixed with sodium bicarbonate.

The injection will be performed once into the painful muscle trigger points under sterile conditions.

Pain levels will be assessed using a simple pain scale, and muscle activity will be measured using a non-invasive technique called surface electromyography (sEMG), which records muscle electrical activity. These measurements will be taken before the injection, immediately after, and during follow-up visits.

Participants may experience mild discomfort during or after the injection, but all procedures are routinely used in clinical practice. Safety measures will be in place to manage any possible side effects.

The goal of this study is to determine whether the combined injection provides better pain relief, improves muscle function, and enhances patient comfort compared to lidocaine alone.

研究概览

详细说明

Study Overview

This study is a randomized, parallel-group, single-blind clinical trial designed to evaluate the clinical effectiveness of adding sodium bicarbonate to lidocaine in the treatment of myofascial pain syndrome (MPS). The study compares outcomes between lidocaine alone and buffered lidocaine using surface electromyography (sEMG) and pain assessment tools.

Background

Myofascial pain syndrome is a prevalent musculoskeletal disorder characterized by the presence of myofascial trigger points, leading to localized or referred pain, functional limitation, and reduced quality of life. Although trigger point injections with lidocaine are widely used and provide rapid pain relief, their effects are often temporary and may require repeated administration.

Buffered lidocaine, achieved by adding sodium bicarbonate, has been proposed to enhance anesthetic performance by increasing the pH of the solution. This increases the proportion of the non-ionized form of lidocaine, facilitating faster onset of action, improved tissue penetration, and reduced pain during injection. However, its role in managing MPS has not been sufficiently established.

Rationale

There is currently no consensus regarding the optimal injectable solution for trigger point therapy. This study aims to determine whether buffering lidocaine with sodium bicarbonate improves clinical outcomes in terms of pain reduction, patient comfort, and muscle function compared to lidocaine alone.

Objectives

The primary objective is to evaluate the effect of adding sodium bicarbonate to lidocaine on pain reduction in patients with myofascial pain syndrome.

Secondary objectives include:

Assessing pain experienced during injection Evaluating changes in muscle activation patterns and functional recovery Study Design Type: Randomized controlled clinical trial Design: Parallel, two-arm Allocation ratio: 1:1 Blinding: Single-blind (participants blinded) Framework: Superiority Participants

Participants will be recruited from outpatient clinics of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Cairo University.

Eligible participants include patients diagnosed with myofascial pain syndrome presenting with active trigger points and moderate to severe pain.

Interventions

Participants will be randomly assigned into two groups:

Control Group: Injection with 2% lidocaine alone Intervention Group: Injection with 2% lidocaine buffered with sodium bicarbonate (8.4%)

The buffered solution will be freshly prepared immediately prior to injection under aseptic conditions.

All injections will be administered into identified trigger points using a standardized technique.

Outcome Measures Primary Outcome

Pain reduction assessed using:

Visual Analog Scale (VAS) Surface electromyography (sEMG) Secondary Outcome Pain during injection (VAS) Tertiary Outcome Changes in muscle activation during voluntary contraction (sEMG)

Assessments will be conducted at baseline, immediately after injection, and at follow-up visits.

Safety Considerations

All procedures will follow strict aseptic protocols. Patients will be monitored immediately after injection for any adverse reactions.

Possible risks include:

Pain at injection site Vasovagal reactions Local tissue injury Rare allergic reactions

Risk mitigation measures include proper injection technique, dose calculation, aspiration before injection, and availability of emergency equipment.

Data Collection and Analysis

Data will be collected using standardized forms and stored securely. Statistical analysis will be performed to compare outcomes between both groups, with significance set at p ≤ 0.05.

Ethical Considerations

The study will be conducted following ethical guidelines and will require approval from the institutional ethics committee. Written informed consent will be obtained from all participants prior to enrollment. Participant confidentiality will be strictly maintained.

Expected Impact

This study aims to provide evidence on whether buffering lidocaine with sodium bicarbonate improves treatment outcomes in myofascial pain syndrome. The findings may help guide clinical practice toward more effective and comfortable treatment options.

研究类型

介入性

注册 (估计的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Cairo Governorate
      • Cairo、Cairo Governorate、埃及、22023

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

Patients aged 16 to 70 years Clinical diagnosis of myofascial pain syndrome (MPS) Presence of active myofascial trigger points Pain duration ≥ 3 months Pain intensity ≥ 4 on the Visual Analog Scale (VAS) Trigger points located in accessible muscles No trigger point injection in the affected area within the past 3 months Ability and willingness to provide informed consent Willingness to comply with study procedures and follow-up visits

Exclusion Criteria:

Known allergy or hypersensitivity to lidocaine, sodium bicarbonate, or other amide-type local anesthetics Current use of anticoagulants or presence of bleeding disorders Local or systemic infection at or near the injection site History of fibromyalgia, cancer-related pain, or central pain syndromes Major psychiatric disorders (e.g., schizophrenia, severe depression) Recent trauma or surgery to the neck, shoulder, or back within the past 6 months Use of analgesics (e.g., NSAIDs, opioids) within 5 days prior to injection Severe systemic diseases (e.g., uncontrolled diabetes, liver failure, kidney failure, severe cardiovascular disease)

-

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Lidocaine 2% (control group)
Participants in this group will receive a single-session trigger point injection using 2% lidocaine without any additives. The injection will be administered into the identified myofascial trigger points using a standardized technique under aseptic conditions.
2% lidocaine (preservative-free, without vasoconstrictor) will be administered via intramuscular injection into the identified trigger points. Approximately 1.8 mL will be injected per point using a sterile 25-27 gauge needle. The injection will be performed using a standardized "fast-in, fast-out" (peppering) technique.
实验性的:Lidocaine + Sodium Bicarbonate (buffered group)
Participants in this group will receive a single-session trigger point injection using 2% lidocaine combined with sodium bicarbonate. The buffered solution is intended to reduce injection pain and enhance anesthetic effectiveness.
A buffered anesthetic solution will be prepared immediately before injection by mixing 2% lidocaine with 8.4% sodium bicarbonate in a ratio of 9:1 (1.8 mL lidocaine + 0.2 mL sodium bicarbonate per injection point). The solution will be administered via intramuscular injection into trigger points using a sterile 25-27 gauge needle and standardized injection technique.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Reduction in Pain Intensity
大体时间:Baseline, immediately after injection, and 2 weeks post-injection
Pain intensity will be assessed using the Visual Analog Scale (VAS) (0-10). In addition, surface electromyography (sEMG) will be used to objectively evaluate muscle activity at rest (MVC%). A reduction in VAS scores and sEMG activity indicates improvement.
Baseline, immediately after injection, and 2 weeks post-injection

次要结果测量

结果测量
措施说明
大体时间
Pain During Injection
大体时间:Immediately after injection
Pain experienced during the injection procedure will be measured using the Visual Analog Scale (VAS) (0-10), immediately after completion of the injection.
Immediately after injection

其他结果措施

结果测量
措施说明
大体时间
Change in Muscle Activation Pattern
大体时间:Baseline and 2 weeks post-injection
Changes in muscle activation during voluntary contraction will be assessed using surface electromyography (sEMG) (MVC%). Improvement indicates better functional muscle recovery.
Baseline and 2 weeks post-injection

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Khalid elhayes, professor、cairo university oral and maxillofacial surgery department
  • 研究主任:Abdelmoez Mohamed El-Sharkawy, Associate professor、cairo University -oral and maxillofacial surgery department
  • 研究主任:Adham Yehia Zakaria, Lecturer、cairo university oral and maxillofacial surgery department
  • 研究主任:Eman hassan Elzamarany, lecturer、Department of Neurology and Clinical Physiology Faculty of Medicine, Cairo University
  • 首席研究员:ola mohamed Abdelfath、cairo university oral and maxillofacial surgery department

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月1日

初级完成 (估计的)

2026年9月1日

研究完成 (估计的)

2026年10月1日

研究注册日期

首次提交

2026年4月30日

首先提交符合 QC 标准的

2026年5月1日

首次发布 (实际的)

2026年5月7日

研究记录更新

最后更新发布 (实际的)

2026年5月7日

上次提交的符合 QC 标准的更新

2026年5月1日

最后验证

2026年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅